Clinical Trial

Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss of the scalp or any hair-bearing surface. Alopecia areata affects approximately 2% of the general population. AA has a significant influence on patients' quality of life and may induce psychological disorders. In AA, CD4+ and CD8+ T-cells violate the immune privilege of the anagen hair follicle, leading to loss of the growing hair shaft. A genome-wide association study demonstrated a genetic predisposition to AA . Additionally, environmental insults, such as viral infections, trauma, or psychosocial stress, have also been suspected to possibly contribute to the development of the disease . The clinical manifestations of AA vary from small well-defined patches of hair loss to the diffuse involvement of the scalp or the entire body. The majority of AA patients experience unpredictable relapsing and remitting episodes. In a number of patients, it can be persistent, especially when the hair loss is extensive.
Trial Details
NCT Number NCT06399783
Lead Sponsor Assiut University
Conditions Alopecia Areata
Enrollment 54 participants
Start Date 2024-10-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-06